Ssytemic effects of intravenous polyriboinosinic-polyribocytidylic acid in man.
To investigate the systemic, clinical and laboratory effects of iv polyriboinosinic-polyribocytidylic acid (poly I-poly C), 32 doses of poly I-poly C were administered to 22 patients. Doses between 1 and 10 mg/kg induced the formation of serum interferon (IF) and fever. Whereas a direct relationship was seen between the poly I-poly C dose and fever, serum IF levels were not significantly changed by increasing the dose of poly I-poly C over a log range from 1 to 10 mg/kg. Transient abnormalities were noted in liver function tests in 4 of 13 patients who received greater than 6.0 mg/kg. Other laboratory changes were confined to an increase in the absolute granulocyte count that paralleled fever development and abnormalities in coagulation parameters of 1 patient. In vitro lymphocyte DNA synthesis in response to mitogens was transiently impaired at times corresponding to serum IF appearance. These studies have established dose levels of poly I-poly C that can be safely administered to man with minimal toxicity and result in IF induction.
D000328:Adult; D000368:Aged; D002478:Cells, Cultured; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007275:Injections, Intravenous; D007372:Interferons / Q000097:blood*; D007938:Leukemia / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy; D007958:Leukocyte Count; D008099:Liver / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*; D009504:Neutrophils / Q000187:drug effects; D011070:Poly I-C / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D007372:Interferons; D011070:Poly I-C